Allakos is developing AK002 for eosinophilic gastritis (EG) with or without eosinophilic gastroenteritis, a condition identified by eosinophilic inflammation of the stomach or stomach and small intestine. AK002 has been tested in a randomized, double-blind, placebo-controlled Phase 1 clinical trial in healthy volunteers. All doses tested resulted in complete depletion of blood eosinophils within one hour after AK002 administration. The ability to deplete eosinophils may be of benefit in patients with eosinophilic driven inflammation.
Allakos is developing AK002 in patients with urticaria and is currently conducting a Phase 1 clinical trial. The trial is enrolling patients with chronic idiopathic, cholinergic, and dermatographic urticaria. Urticaria is caused by the inappropriate activation of mast cells in the skin. Inhibition of mast cells with AK002 may help resolve the symptoms of urticaria.
Severe Allergic Conjunctivitis
Allakos is developing AK002 in patients with severe allergic conjunctivitis and is currently conducting a Phase 1 clinical trial. The trial is enrolling patients with atopic keratoconjuctivitis, vernal keratoconjunctivitis, and perennial allergic conjunctivitis refractory to topical treatments. Patients with severe allergic conjunctivitis have eosinophil and mast cell driven inflammation that can cause permanent eye damage.
Indolent Systemic Mastocytosis
Allakos is developing AK002 for patients with indolent systemic mastocytosis (ISM) and is currently conducting a Phase 1 clinical trial. ISM is a disorder where there are increased numbers of mast cells throughout the body with symptoms related to mast cell inflammatory mediator release. AK002’s ability to inhibit mast cells may be of benefit to patients with ISM.